Stability-Modulating Linkers for Antibody Drug Conjugates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional antibody-drug conjugates (ADCs) face challenges in achieving optimal stability, leading to premature payload release in plasma and suboptimal payload delivery to tumor sites, requiring higher dosing levels and affecting efficacy and safety.
Innovation Solution
Incorporation of specific chemical features into the amine-containing conjugation handles of ADC linkers, allowing for modulation of ADC stability through transglutaminase-mediated conjugation, enabling fine-tuning of stability in vivo to optimize payload release at the target site.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional ADC conjugation methods are used, then ADC structure is formed, but payload is released prematurely in plasma
Solution Approach 1:
The patent modifies the chemical parameters of the linker by incorporating specific amino acid sequences (Val-Cit, Val-Omt, P1, P2, P3) with different stability characteristics. These parameter changes in the linker structure enable control over payload release timing, preventing premature release in plasma while maintaining stability during circulation.
Solution Approach 2:
The patent creates composite linker structures combining multiple amino acid residues (Valine, Citrulline, Ornithine, etc.) with specific sequences and configurations. These composite peptide linkers provide both stability in plasma and controlled cleavage in target cells, resolving the contradiction between maintaining ADC integrity and enabling payload release.
2Reliability
If ADC stability is increased to prevent premature payload release, then payload delivery to tumor site is reduced
Solution Approach 1:
The patent applies different local qualities to different parts of the linker structure. Specific amino acid sequences (Val-Cit for stability, Val-Omt for cleavability) are positioned at specific locations within the linker to create local variations in stability. This allows the ADC to maintain overall stability while having specific regions that enable controlled payload release at the target site.
Solution Approach 2:
The patent introduces dynamic characteristics to the linker by using proteolytically cleavable peptide sequences that can change their structural and functional properties in response to different biological environments. The linker transitions from a stable state in plasma to a cleavable state in endosomal/lysosomal compartments, enabling adaptive payload release.
3Quantity of substance
If higher ADC dosing levels are used to achieve desired payload exposure, then safety and efficacy are affected
Solution Approach 1:
The patent extracts the payload release function from the ADC structure by using cleavable linker sequences that can be selectively broken down in target cells. This separation allows the ADC to remain stable during circulation at lower doses while releasing the payload efficiently at the target site, reducing systemic toxicity associated with higher dosing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for precise control of ADC stability, enhancing in vivo efficacy and safety by optimizing the therapeutic index through targeted payload release, thereby improving treatment outcomes.
Implementation Method 1
Conjugation using a transglutaminase provides the advantages of high selectivity, simplified reaction procedures, and mild reaction conditions
Implementation Method 2
Transglutaminases belong to a family of enzymes that catalyze acyl addition to a primary amine
Implementation Method 3
Such linkages purportedly undergo cleavage upon internalization into antigen-targeted cells and exposure of the ADC to the degradative proteolytic environment found in endosomal and lysosomal organelles
Data Source
AI summary
The present invention provides stability-modulated antibody-drug conjugates, stability-modulating linker components used to make these stability-modulated antibody-drug conjugates, therapeutic methods using stability-modulated antibody-drug conjugates, and methods of making stability modulating linkers and stability-modulated antibody-drug conjugates.